Outcomes of Interleukin-2 Receptor Antagonist Induction Therapy in Standard-Risk Renal Transplant Recipients Maintained on Tacrolimus: A Systematic Review and Meta-Analysis.

Ali, Hatem; Mohamed, Mahmoud M; Sharma, Ajay; Fulop, Tibor; Halawa, Ahmed

Ali, Hatem; Mohamed, Mahmoud M; Sharma, Ajay; Fulop, Tibor; Halawa, Ahmed.

Afiliação

Ali H; Renal Department, University Hospitals of Coventry and Warwickshire, Coventry, United Kingdom.
Mohamed MM; Division of Nephrology, Department of Medicine, University of Tennessee, Knoxville, Tennessee, USA.
Sharma A; Institute of Medical Sciences, Faculty of Medicine, University of Liverpool, Liverpool, United Kingdom.
Fulop T; Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Halawa A; Medicine Service, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA.

Am J Nephrol ; 52(4): 279-291, 2021.

Article em En | MEDLINE | ID: mdl-33887727

Assuntos

Imunossupressores/uso terapêutico; Transplante de Rim; Receptores de Interleucina-2/antagonistas & inibidores; Tacrolimo/uso terapêutico; Humanos; Quimioterapia de Indução; Quimioterapia de Manutenção; Medição de Risco; Resultado do Tratamento

Palavras-chave

Interleukin-2 receptor antagonist; Kidney transplant recipient; Mycophenolate mofetil; Panel-reactive antibody

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Interleucina-2 / Transplante de Rim / Tacrolimo / Imunossupressores Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google